Junfen Xu

2.4k total citations · 2 hit papers
54 papers, 1.6k citations indexed

About

Junfen Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Junfen Xu has authored 54 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 27 papers in Cancer Research and 15 papers in Oncology. Recurrent topics in Junfen Xu's work include Cancer-related molecular mechanisms research (20 papers), MicroRNA in disease regulation (14 papers) and Circular RNAs in diseases (14 papers). Junfen Xu is often cited by papers focused on Cancer-related molecular mechanisms research (20 papers), MicroRNA in disease regulation (14 papers) and Circular RNAs in diseases (14 papers). Junfen Xu collaborates with scholars based in China, United States and Finland. Junfen Xu's co-authors include Weiguo Lü, Xing Xie, Yifeng Fang, Yuanming Shen, Xiaoyun Wan, Fenfen Wang, Feng Ye, Jiansong Zhou, Xiao Liang and Xiujun Cai and has published in prestigious journals such as Proceedings of the National Academy of Sciences, ACS Nano and PLoS ONE.

In The Last Decade

Junfen Xu

46 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer

2022 138 citations Junfen Xu, Yifeng Fang et al. Clinical Cancer Research profile →
Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

2024 67 citations Junfen Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junfen Xu China	20	1.1k	982	313	214	197	54	1.6k
Hua‐Chien Chen Taiwan	25	957 0.9×	688 0.7×	556 1.8×	118 0.6×	104 0.5×	44	1.6k
Chunlin Ou China	26	1.3k 1.2×	897 0.9×	340 1.1×	224 1.0×	127 0.6×	76	1.9k
Hao Bo China	23	1.2k 1.1×	1.1k 1.1×	241 0.8×	150 0.7×	146 0.7×	65	1.7k
Pavel Fabián Czechia	22	1.3k 1.1×	1.2k 1.2×	463 1.5×	240 1.1×	87 0.4×	95	2.0k
Fulin Qiang China	23	814 0.7×	556 0.6×	349 1.1×	126 0.6×	173 0.9×	37	1.3k
Trevor G. Shepherd Canada	26	1.1k 1.0×	406 0.4×	644 2.1×	192 0.9×	175 0.9×	64	1.8k
Jung‐Joo Choi South Korea	24	830 0.7×	508 0.5×	316 1.0×	96 0.4×	191 1.0×	41	1.5k
Salma Khan United States	18	1.2k 1.1×	599 0.6×	218 0.7×	135 0.6×	50 0.3×	38	1.5k
Xiaoyuan Chu China	33	2.0k 1.8×	1.4k 1.5×	557 1.8×	272 1.3×	184 0.9×	91	2.7k
Shengming Dai China	17	1.1k 1.0×	838 0.9×	135 0.4×	65 0.3×	105 0.5×	35	1.5k

Countries citing papers authored by Junfen Xu

Since Specialization

Citations

This map shows the geographic impact of Junfen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junfen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junfen Xu more than expected).

Fields of papers citing papers by Junfen Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junfen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junfen Xu. The network helps show where Junfen Xu may publish in the future.

Co-authorship network of co-authors of Junfen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Junfen Xu. A scholar is included among the top collaborators of Junfen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junfen Xu. Junfen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Junfen, Lijuan Lv, Xiufeng Huang, et al.. (2025). Minimally invasive diagnosis of precancerous cervical lesions using single-cell peripheral immune atlas. Cell Reports Medicine. 6(6). 102149–102149.

Gao, Xueyan, et al.. (2025). Clinicopathological and prognostic factor analyses of primary fallopian tube carcinoma and high-grade serous ovarian cancer: a single-institution retrospective study. World Journal of Surgical Oncology. 23(1). 8–8.

Xu, Junfen, et al.. (2025). Efficacy of 5-aminolevulinic acid photodynamic therapy versus observation for cervical low-grade squamous intraepithelial lesion with type 3 transformation zone. Photodiagnosis and Photodynamic Therapy. 54. 104679–104679. 1 indexed citations

Xu, Shanshan, et al.. (2024). FXN targeting induces cell death in ovarian cancer stem-like cells through PRDX3-Mediated oxidative stress. iScience. 27(8). 110506–110506. 7 indexed citations

Luo, Ying, Yanfei Liu, Yuanyuan Deng, et al.. (2024). Oncoproteins E6 and E7 upregulate topoisomerase I to activate the cGAS-PD-L1 pathway in cervical cancer development. Frontiers in Pharmacology. 15. 1450875–1450875. 7 indexed citations

Xu, Junfen, et al.. (2024). Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma. Journal of Zhejiang University SCIENCE B. 25(8). 686–699.

Xu, Junfen, et al.. (2024). Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment. Cancer Letters. 593. 216928–216928. 7 indexed citations

Xu, Junfen, et al.. (2023). Advances in immunotherapy for gynecological malignancies. Critical Reviews in Oncology/Hematology. 188. 104063–104063. 14 indexed citations

Xu, Junfen, Yifeng Fang, Kelie Chen, et al.. (2022). Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 28(16). 3590–3602. 138 indexed citations breakdown →

10.

Tang, Sangsang, et al.. (2022). Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. Cell Death and Disease. 13(9). 826–826. 46 indexed citations

11.

Zheng, Zhi‐Ming, Xiaojing Chen, Xiaoyun Cai, et al.. (2022). RNA-binding protein MEX3D promotes cervical carcinoma tumorigenesis by destabilizing TSC22D1 mRNA. Cell Death Discovery. 8(1). 250–250. 13 indexed citations

12.

Cen, Yixuan, Yanan Zhang, Lu Zhao, et al.. (2021). hsa_circ_0005358 suppresses cervical cancer metastasis by interacting with PTBP1 protein to destabilize CDCP1 mRNA. Molecular Therapy — Nucleic Acids. 27. 227–240. 17 indexed citations

13.

Lü, Bingjian, Haiyan Shi, Ying Shao, & Junfen Xu. (2021). Ovarian Metastasis by Gastric-type Endocervical Adenocarcinoma: A Clinicopathologic Description of 12 Cases. International Journal of Gynecological Pathology. 41(4). 356–365. 1 indexed citations

14.

Xu, Junfen, Yuanming Shen, Conghui Wang, et al.. (2021). Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors. Cell Death Discovery. 7(1). 259–259. 16 indexed citations

15.

Xu, Junfen, et al.. (2020). circEYA1 Functions as a Sponge of miR-582-3p to Suppress Cervical Adenocarcinoma Tumorigenesis via Upregulating CXCL14. Molecular Therapy — Nucleic Acids. 22. 1176–1190. 27 indexed citations

16.

Chen, Tingting, et al.. (2019). Transcriptome sequencing profiles of cervical cancer tissues and SiHa cells. Functional & Integrative Genomics. 20(2). 211–221. 30 indexed citations

17.

Xu, Junfen, Xiaoyun Wan, Xiaojing Chen, et al.. (2016). miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. Scientific Reports. 6(1). 28968–28968. 38 indexed citations

18.

Fang, Yifeng, Hong Yu, Xiao Liang, Junfen Xu, & Xiujun Cai. (2014). Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biology & Therapy. 15(9). 1268–1279. 129 indexed citations

19.

Li, Yang, Fenfen Wang, Ying Li, et al.. (2014). MicroRNA Detection in Cervical Exfoliated Cells as a Triage for Human Papillomavirus–Positive Women. JNCI Journal of the National Cancer Institute. 106(9). 61 indexed citations

20.

Wang, Fenfen, Li Yang, Jiansong Zhou, et al.. (2011). miR-375 Is Down-Regulated in Squamous Cervical Cancer and Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1. American Journal Of Pathology. 179(5). 2580–2588. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact